- Company will also host a reception with Key Opinion Leaders in New Orleans - ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --   Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the team will present at

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022 Initiation of Phase 1 study for MP0533 expected by year end Continued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers;

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will issue a press release summarizing its

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of key preclinical

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) --  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its team will

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 12, 2022 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR:   Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its management team